News | Cardiovascular Surgery | September 06, 2018

Bilateral Artery Use Does Not Improve 10-Year CABG Outcomes

ART study reveals using two arteries during cardiovascular surgery does not improve mortality rates a decade later

Bilateral Artery Use Does Not Improve 10-Year CABG Outcomes

September 6, 2018 — While it is firmly established that the use of one internal thoracic artery can improve life expectancy in coronary artery bypass graft (CABG) surgery compared to vein grafts, it is not known if there are additional benefits with the use of a second artery. This was explored in the ten-year outcomes of the Arterial Revascularisation Trial (ART) presented in a Hot Line Session at the European Society of Cardiology (ESC) Congress 2018, Aug. 25-28 in Munich, Germany.

CABG surgery is indicated in patients with angina and advanced coronary artery disease (CAD). With about 1 million operations per year globally, it is one of the most common major surgical procedures undertaken worldwide. Establishing the best methods for CABG is therefore a key element of successful management of patients with advanced CAD, who have narrowed coronary arteries and are at higher risk of limited exercise capacity due to angina , myocardial infarction and death.

ART tested whether routine use of two internal thoracic arteries, compared to the standard single internal thoracic artery, could reduce the risk of dying over a 10-year period in patients undergoing CABG surgery.

Between 2004 and 2007, the trial enrolled 3,102 patients with symptomatic coronary disease scheduled to undergo CABG at 28 centers in seven countries (U.K., Poland, Australia, India, Brazil, Austria and Italy). A total of 1,548 patients were randomly allocated to bilateral and 1,554 patients to single internal thoracic artery grafts. Additional arterial or vein grafts were used at the discretion of the responsible surgeon. The primary outcome was death from any cause at 10 years. The secondary outcome was a composite of death from any cause, myocardial infarction or stroke.

The average age of participants was 64 years and 24 percent were women. In the bilateral graft group, 14 percent actually received a single internal thoracic artery graft, while 22 percent in the single internal thoracic artery group also received an additional radial artery graft.

At ten years 315 (20.4 percent) and 329 (21.2 percent) patients died in the bilateral and single graft groups, respectively (hazard ratio [HR] 0.96, 95 percent confidence interval [CI] 0.82–1.12, p=0.58). The secondary outcome occurred in 385 (24.9 percent) and 425 (27.4 percent) patients in the bilateral and single graft groups, respectively (HR 0.90, 95 percent CI 0.78–1.03, p=0.12). Results appeared to be more favorable in patients who had bilateral graft surgery done by surgeons who performed more operations in the trial.

In an exploratory analysis, patients who received any two arterial grafts (internal thoracic or radial) appeared to have a lower mortality (HR 0.79, 95 percent CI 0.64–0.97) and composite of death, myocardial infarction or stroke (HR 0.80, 95 percent CI 0.69–0.93) compared to those who received a single arterial graft. Although these findings are relevant, they are not a randomized comparison and require confirmation in future trials.

Overall, ART was not able to confirm that a strategy of routine bilateral internal thoracic artery grafting was superior to routine single internal thoracic artery grafting for patients undergoing CABG. Possible explanations include the high rate of patients who were randomized to receive a bilateral internal thoracic artery but actually received a single internal thoracic artery, and in those assigned a single internal thoracic artery graft about one-fifth actually received an additional arterial graft in the form of a radial artery. Both factors could have reduced the true efficacy of bilateral internal thoracic artery grafts. Furthermore, a high use of guideline directed medical therapy — including aspirin, statins, beta-blockers and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers — in both groups may have narrowed any potential differences between the groups.

Prof. David Taggart, chief investigator and professor of cardiac surgery at the University of Oxford, U.K., said, “ART is one the largest trials with the longest duration of follow-up ever undertaken in cardiac surgery to guide future practice with regards to conduit selection for CABG. While the trial did not show that using two internal thoracic arteries is superior to one, it raises the possibility that any two arterial grafts (internal thoracic or radial) may provide better outcomes than a single graft for patients undergoing CABG surgery.”

For more information: www.escardio.org

Related ESC Content

Bleeds and Benefit With Aspirin Balanced in Diabetes Patients

Effect of Daily Aspirin on First-Time Heart Attack and Stroke Risk Inconclusive

AI-Driven Blood Test Accurately Diagnoses Peripheral Artery Disease in Diabetic Patients

Weight Loss Drug Does Not Increase Cardiovascular Events

Extended Post-Hospital Oral Anticoagulant Use Reduces Non-Fatal Blood Clots


Related Content

News | Cardiovascular Clinical Studies

February 15, 2024 — Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and ...

Home February 15, 2024
Home
News | Cardiovascular Clinical Studies

January 3, 2024 — Cardionomic, Inc., a Minneapolis medical device company, is pleased to announce the completion of ...

Home January 03, 2024
Home
News | Cardiovascular Clinical Studies

December 19, 2023 — Peerbridge Health has announce the successful completion and findings of its prospective ...

Home December 19, 2023
Home
News | Cardiovascular Clinical Studies

December 14, 2023 — Published results of a large, national heart attack study show that patients with a life-threatening ...

Home December 14, 2023
Home
News | Cardiovascular Clinical Studies

December 11, 2023 — A world without cardiovascular disease (CVD) is possible, yet millions of lives are lost prematurely ...

Home December 11, 2023
Home
News | Cardiovascular Clinical Studies

December 8, 2023 — Procyrion, Inc., a medical device company dedicated to improving outcomes for patients with cardiac ...

Home December 08, 2023
Home
News | Cardiovascular Clinical Studies

November 29, 2023 — Inari Medical, Inc., a medical device company with a mission to treat and transform the lives of ...

Home November 29, 2023
Home
News | Cardiovascular Clinical Studies

November 29, 2023 — Foldax, Inc., a leader in the development of innovative, polymer heart valves, today announced ...

Home November 29, 2023
Home
Subscribe Now